Supplementary Text

VAC068: Long-term safety monitoring

Follow-up clinic visits at dC+45 and dC+90 gave rise to no safety concerns or indication of relapsing infection, with negative qPCR readings recorded at both time-points. Ongoing annual follow-up by email will continue for 5 years post-CHMI, however, as of time of writing (May 2021; 3 years post-primaquine treatment) no relapse of *P. vivax* has been diagnosed for either volunteer. One volunteer did report symptoms of rapid-onset fever, chills, myalgia and headache, following a prodrome of fatigue and sore throat, 12 months post-CHMI. However, immediate testing for *P. vivax* by qPCR (plus RDT and thick film microscopy) was negative and fevers resolved with no specific treatment within 3 days, with residual symptoms fully resolving within 6 days. The working diagnosis was an intercurrent viral infection (blood tests showed a leukocytosis (11.96 x10⁹/mL) with a relative grade 1 neutrophilia (10.7 x10⁹/mL) and grade 3 lymphocytopenia (0.47 x10⁹/mL); CRP 37 mg/L; urea, creatinine and liver function tests within normal limits). The same volunteer had a similar short-lived febrile illness 20 months and then 22 months post-CHMI but both resolved spontaneously after a few days with no specific treatment and no need for medical attendance.

Supplementary Figures

Α

Mosquito Batch Number	Mosquitoes Dissected for Oocyst Count (n)	Mean [range] Oocyst Count on Days 6-7	Mosquitoes Dissected for Spz Count (n)	Median [range] Spz Score in Salivary Glands on Day 14	PvCSP- typing	Genotyping
C01-001	5	9 [4-12]	N.D.	N.D.	VK210	Probably mixed- infection
C05-001	10	3 [0-6]	10	+2 [0 to +4]	VK210	Mono- infection
C05-002	5	19 [15-35]	N.D.	N.D.	VK210	Mixed- infection (2 strains)

В



Figure S1. Results of mosquito batch analyses conducted in real-time.

(A) Three independent batches of mosquitoes were prepared in Thailand. Oocyst count data from dissected midguts and sporozoite (spz) count data from dissected salivary glands are reported. Score of +2 indicates >10-100 spz observed; score of +4 indicates >500 spz observed; 0 indicates negative; N.D. = not done. Genotyping of patient blood samples was performed to assess multiplicity of *P*.

vivax infection, with extracted DNA processed using a SNP barcode panel as described by the MalariaGEN network (1). Out of the three samples, the barcode sequences for two contained heterozygous genotype calls, suggesting the presence of more than one genotype within the infection. One blood sample (C05-001) had homozygous calls at all single nucleotide polymorphisms (SNPs), suggesting that it contained only a single *P. vivax* genotype. (**B**) Nested PCR to test for presence of *P. falciparum*, *P. malariae*, *P. ovale curtisi* and *P. ovale wallikeri* DNA. Amplified band at ~300 bp shown presence of DNA from each species of *Plasmodium* parasite. Positive control samples were tested in five replicates, with successful amplification in 5/5 cases for *P. falciparum* and *P. malariae*, but less reliable amplification for the two subspecies of *P. ovale*. Each of the three donor blood samples used to produce the batches of mosquitoes were tested in ten replicates. All test samples were negative. (**C**) The same PCR assay was performed using primers for *P. vivax*. All ten replicates for each donor blood sample were positive. Non-infected blood sample control was negative (tested in five replicates).



Figure S2. VAC068 flow chart of study design and volunteer recruitment.

Enrolment into the VAC068 study began in April 2018. Eight volunteers underwent pre-screening for O- blood group prior to full screening. Three eligible volunteers were identified, of whom one was a back-up (in case a volunteer withdrew prior to CHMI) and two proceeded to enrolment and underwent *P. vivax* CHMI delivered by mosquito-bite on 13 April 2018. Clinical follow-up continued until 90 days after challenge (dC+90) and was completed by 16 July 2019. Annual follow-up by email correspondence will continue for 5 years. Volunteer demographics are summarized in **Table S1**.



Figure S3. Results of primaquine test dose at screening for the VAC068 volunteers.

Plasma concentrations of (**A**) primaquine (parent drug) and (**B**) carboxyprimaquine (metabolite) versus time in the two VAC068 volunteers following a single 30 mg oral dose of primaquine. Results for carboxyprimaquine, the major observed plasma metabolite of primaquine, are shown for completeness, but this is not produced primarily via CYP2D6 metabolism (2) and is, therefore, an unproven indicator of CYP2D6 phenotype and primaquine efficacy. (**C**) Pharmacokinetic parameters of primaquine. [†] Data previously reported by Bennett *et al.* (3) indicated that these kinetic parameters were significantly different between subjects that relapsed with *P. vivax* versus those that did not, consistent with decreased metabolism of primaquine. The primaquine datasets for both volunteers in VAC068 are consistent with the expected ranges for CYP2D6 extensive metabolizers as reported by Bennett *et al.* (3).



Figure S4. VAC068 adverse event data following *P. vivax* sporozoite CHMI.

(A) The solicited systemic AEs recorded at the indicated time-points during the CHMI period are shown as the maximum severity reported by each volunteer and as a percentage of the volunteers reporting each individual AE (n=2). Color-coding refers to AE grading: 0 = none; 1 = mild; 2 =moderate; 3 = severe. 48h-pre = the 48 hour period prior to blood donation; Donation = time-point of blood donation; +1, +2 and +5 days post-treatment (T). (B) Percentage of all volunteers (n=2) with AEs in recorded physical observations during the CHMI period (from day of challenge up until 90 days post-challenge). Pyrexia relates to the measured temperature during clinic visits. (C) AEs possibly relating to anti-malarial treatment (from day T+1 until completion of primaquine treatment course on T+16) shown as a percentage of all volunteers (n=2). Page 6 of 24



Figure S5. VAC069A flow chart of study design and volunteer recruitment.

Enrolment into the VAC069A study began in January 2019. Six volunteers (of the nine screened) were enrolled into the blood-stage CHMI trial – two into each dose group (neat, 1:5, 1:20 dilution). One volunteer in the 1:20 dose group completed the C+28 follow-up but then withdrew consent. The five remaining volunteers completed their follow-up until C+90. Across the groups, 4 males and 2 females were enrolled, the mean age was 27 years (range 18 – 33 years). None had previously travelled to malaria-endemic regions.



Figure S6. VAC069A adverse event data following P. vivax PvW1 blood-stage CHMI.

(A) Percentage of all volunteers (n=6) with AEs in recorded physical observations (from day of challenge up until 90 days post-challenge). Pyrexia relates to the measured temperature during clinic visits. (B) AEs possibly relating to anti-malarial treatment, recorded from day after starting treatment (T+1) until 28 days post-challenge (C+28, approximately 10 days post-completion of treatment), shown as a percentage of all volunteers (n=6). Color-coding refers to AE grading: 0 = none; 1 = mild; 2 = moderate; 3 = severe. (C) The laboratory AEs recorded at the indicated time-points during the CHMI period (day of challenge until 90 days post-challenge) are shown as the maximum severity

reported for each volunteer and as a percentage of the volunteers reporting each individual AE (n=6). Baseline = prior to CHMI (C-1); Diagnosis = time-point of malaria diagnosis; +2 and +6 days post-treatment (T+2, T+6); C+28 = 28 days post-CHMI.



Figure S7. Organization of the MSP3 multigene family in PvW1 compared to other *P*. *vivax* isolates.

Organization of the MSP3 multigene family in PvW1 is compared to *P. vivax* isolates: PvP01 (4) and Salvador-1, India-7, North Korean, Mauritania-1, Brazil-1 (5). Flanking genes are shown and are syntenic across all isolates, as are MSP3.1, MSP3.2, MSP3.3, MSP3.G, MSP3.10 and MSP3.11. There is variability in the central region of the MSP3 region in the presence or absence and copy number of MSP3.4, MSP3.5, MSP3.6, MSP3.7, MSP3.8 and MSP3.9.

A PvCSP

 1
 1
 2
 3
 4
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 4
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9
 9

B Pvs25

 1
 1
 2
 3
 4
 9
 6
 7
 8
 9
 100
 110
 120

 PWEL10102
 PWEL10102

C PvDBP

70 80 Inerseenikykygvtelp Inerseenikykygvtelp PVW1 MKGKNRSLFVLLVLLL PVP01_0623800 MKGKNRSLFVLLVLLL PVX 110810 MKGKNRSLFVLLVLLL LLERTIETL LLERTIETL 190 180 150 160 170 PvW1 DGGDKT PVP01_0623800 DGGDKT PVX_110810 DGGDKT
 PvW1
 RRYQLCMKE1

 PVP01_0623800
 RRYQLCMKE1

 PVX_110810
 RRYQLCMKE1
 460 390 EPQIYR EPQIYR EPQIYR 400 NGRDYVS NGRDYVK 410 PvW1 PVP01_0623800 PVX 110810 IWICK N 540 510 550 PvW1 PvP01_0623800 PvX_110810 630 640 650 AGKENLGASNSRPSESTVEANSPGDDTVN AGKENLGASNSRPSESTVEANSPGDDTVN AGKENLGASNSRPSESTVEANSPGDDTVN PvW1 PVP01_0623800 PVX_110810 SASIPVVSGE SASIPVVSGE NPLVTPYNG: NPLVTPYNG: FABSTRS 77 Q 7 5 Q 760 780 PvW1 PVP01_0623800 PVX_110810 900 SHHLN SHHLN SHHLN 910 NGKLDIH NGKLDIH NGKLDIH 8 9 Q 850 880 PvW1 PVP01_0623800 PVX_110810 IILM. IILM. 1010 1020 1030 1040 1000 1050 PvW1 PVP01_0623800 PVX_110810 SKNLCCSISDFCLNYFDVNSYEY SKNLCCSISDFCLNYFDVYSYEY SKNLCCSISDFCLNYFDVYSYEY

Figure S8. Amino acid sequence alignments of leading *P. vivax* vaccine candidate antigens.

Sequences are aligned for (**A**) sporozoite-stage PvCSP, (**B**) transmission-stage Pvs25, and (**C**) bloodstage PvDBP from PvW1, PvP01 and SalI (labelled PVX). The start and end of region II in PvDBP, present in two clinical vaccine candidates (6, 7), are indicated by the blue arrows (D194-T521, numbered as in SalI). The "DEK epitope" (8) is indicated by the orange arrow.



В





Figure S9. Analysis of gene copy number variation in PvW1.

Illumina reads were mapped to the new PvW1 genome assembly to determine the copy number of genes known to be present in multiple copies in some *P. vivax* isolates. Regions analyzed were (**A**) PvDBP; (**B**) PvMDR1; (**C**) PvDBP2; and (**D**) PvP01_1468200. Individual reads (blue) and coverage (red) are mapped above the genome assembly. The individual genes of interest are highlighted in pink. In all cases Illumina read coverage over the gene of interest appears to be consistent with the flanking

ΤΟ ΟΤΕ ΤΟ ΕΝΤΟΥΤΟΝΙΑ ΤΟ ΤΟ ΕΝΤΟ ΤΟ ΕΝΤΟΥΤΟΝΙΑ ΤΟ ΕΝΤΟΥΤΟΝΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΑΙΤΟΥΤΟΝΙΑΤΙΚΟΥΤΟΝΙΑ ΤΟ ΕΝΤΟΥΤΟΥΤΟΝΙΑ ΤΟ ΕΝΤΟΥΤΟ Α ΕΝΤΟΥΤΟΥΤΟΝΙΑ ΤΟ ΕΝΤΟΥΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΟ Α ΕΝΤΟΥΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ Α Η Α ΤΟ Α ΗΑ Α ΕΙ Α Α Α Ε Ο ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΟΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΤΟ ΕΝΤΟΥΤΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΤΑ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑ ΕΝΤΟ Α ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΤΟ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑΙΑ ΕΝΤΟΥΤΑ ΕΝΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑ ΕΝΤΟΥΤΑ Ε regions suggesting that these genes are present in single copy in the PvW1 genome. Note that the genes labelled PVIVAX are in fact PvW1.

Supplementary Tables

Demographic	Volunteer 1	Volunteer 2
Sex	Female	Male
Age (5-year range)	30-35	20-25
BMI	19.8	23.2
Ethnicity	Caucasian	Caucasian
Blood group (ABO and rhesus)	O negative	O negative
Duffy blood group sero-phenotype	Fya+Fyb+	Fya+Fyb+
G6PD (U/gHb) ^a	9.0	7.7
HLA-type	Typing Done	Typing Done
Hemoglobinopathy screen	Negative	Negative
CMV sero-status	Positive	Positive
EBV sero-status	Positive	Positive
CYP2D6 genotype (predicted phenotype ^b)	CYP2D6*1/*1 (EXT)	CYP2D6*1/*4 (EXT)
CYP2D6 metabolizer phenotype predicted by Activity Score (AS)-Model A ^c	Score 2 (EXT)	Score 1 (EXT)

Table S1. Demographic information for the two volunteers in the VAC068 study.

^a Normal G6PD range = 5.8 - 18.8 U/gHb.

^b Predicted CYP2D6 metabolizer phenotype according to (9) by service provider.

^c Predicted CYP2D6 metabolizer phenotype according to (10), as also used in the study by Bennett et

al. (3). AS-Model A scores range from 0 to 2, with 0 indicating poor or no CYP2D6 activity, 0.5

intermediate, and 1 or 2 indicating normal levels of CYP2D6 activity.

EXT = extensive metabolizer.

Volunteer	DoD	D6.5	D7	D7.5	D8	D8.5	D9	D9.5	D10
01-004	14.5	N	N	N	8	54	80	34	181
01-008	14	N	N	N	N	79	119	119	155
Volunteer	DoD	D10.5	D11	D11.5	D12	D12.5	D13	D13.5	D14
01-004	14.5	302	666	1036	1468	2517	8466	11449	18076
01-008	14	394	1026	1717	1865	2889	8841	16388	16717
Volunteer	DoD	D14.5	T+1	T+2	T+4	T+10	T+16	C+45	C+90
01-004	14.5	31010	610	0.2	1.1	N	N	N	0.4
01-008	14		52	0.9	N	N	N	N	0.0

Table S2: Raw qPCR data (genome copies/mL) for VAC068.

Top row represents day of follow-up visit post mosquito-bite CHMI. Data highlighted in red represent qPCR measurement at time-point of blood donation, also referred to as "day of donation" (DoD) for a particular individual. N = PCR negative for all three triplicate readings in the assay. Squares highlighted in grey indicate negative or a mean reading <20 gc/mL (below minimum positive reporting criteria). Squares highlighted in blue indicate samples taken post-treatment: T+1 indicates 1 day immediately post-treatment initiation; longer-term clinical follow-up occurred at days C+45 and C+90.

Α						
MEDDRA System Organ Class	MEDDRA Higher Level Term	MEDDRA Preferred Term	Subject ID (diagnosis day)	Onset (days post-CHMI)	AE duration (days)	Maximum severity
Gastrointestinal disorders	Gastrointestinal and abdominal pains (excl oral and throat)	Abdominal pain upper	01-004	11	2	Grade 1
Musculoskeletal and connective tissue disorders	Joint related signs and symptoms	Arthralgia	01-004	12	2	Grade 1
Musculoskeletal and connective tissue disorders	Musculoskeletal and connective tissue pain and discomfort	Back pain	01-004	13	1	Grade 1
Cardiac disorders	Cardiac signs and symptoms NEC	Dizziness	01-008	11	1	Grade 1

В

MEDDRA System Organ Class	MEDDRA Higher Level Term	MEDDRA Preferred Term	Subject ID	Onset (days post-CHMI)	AE duration (days)	Maximum severity
Nervous system disorders	Migraine headaches	Migraine	01-004	66	2	Grade 3

С

Laboratory AE	Volunteer	Time-point	Result	Grade	Action taken
Hyber- bilirubinaemia (µmol/L)	01-008	C-1	32	2	No clinical concern, normal ALT/ALP. Resolved by C+14 (20 μmol/L). No action taken.
Anaemia (g/L)	01-008	C+47	123	1	No clinical concern, resolved by C+94 (13.1 g/L). No action taken.
Low white blood cell count (x10 ⁹ /L)	01-004	C+14	3.03	1	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved by C+46 (5.77 x10 ⁹ /L).
Lymphocyto-	01-008	C+14	0.67	2	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved by C+47 (1.95 x10 ⁹ /L).
(x10º/L)	01-004	C+14	0.56	2	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved by C+47 (1.89 x10 ⁹ /L).

Table S3: VAC068 unsolicited, grade 3 and laboratory AEs.

(A) Unsolicited AEs deemed at least possibly (possibly, probably or definitely) related to P. vivax

sporozoite CHMI in all volunteers (n=2) are shown, with MedDRA coding and maximum severity Page 18 of 24 reported. (**B**) Onset and duration of grade 3 AEs: only one grade 3 unsolicited AE (not related to CHMI) was reported by volunteer 01-004. Headache, starting at C+66, lasted 2 days and involved attendance to the volunteer's medical practitioner, but resolved fully. The reported headache was very similar to the volunteer's previous migraines. Grade 3 solicited AEs are shown in **Fig. 1B** and **S4**. (**C**) Laboratory AEs in all volunteers (n=2) in the VAC068 study, from day of challenge until 90 days post-challenge. Blood was drawn for haematology and biochemistry pre-CHMI (day C-1) and post-CHMI on days C+9, C+11, on day of blood donation (C+14) with an additional draw for haematology within 12 hours of treatment, and finally at C+45 and C+90. Blood tests were also carried out at other time-points if clinically indicated. Maximum reported severity is shown, graded as per site-specific grading tables; (Grading: 1 = mild; 2 = moderate; 3 = severe). ALT = alanine aminotransferase; ALP = alkaline phosphatase.

Volunteer	DoD	D0	D1	D2	D2.5	D3	D3.5	D4	D4.5	D5	D5.5	D6	D6.5
01-002	15.5	N	N	N	N	N	N	N	N	N	20	N	7
01-003	12.5	N	N	N	N	N	N	N	N	11	6	11	63
01-005	15	N	N	N	N	N	N	N	N	N	N	N	N
01-006	15	N	N	N	N	N	N	N	N	N	N	N	N
01-007	15.5	N	N	N	N	N	N	N	N	N	N	N	N
01-009	16.5	N	N	N	N	N	N	N	N	N	N	2	15
Volunteer	DoD	D7	D7.5	D8	D8.5	D9	D9.5	D10	D10.5	D11	D11.5	D12	D12.5
01-002	15.5	17	6	17	51	58	95	67	156	301	290	294	411
01-003	12.5	78	45	60	260	508	407	1060	2060	3132	2640	5393	11259
01-005	15	N	5	18	22	72	44	239	250	519	611	972	1735
01-006	15	6	N	21	21	33	38	8	227	266	317	459	986
01-007	15.5	N	N	N	23	32	58	57	204	406	207	616	1227
01-009	16.5	N	N	N	13	15	16	8	55	53	24	76	305
Volunteer	DoD	D13	D13.5	D14	D14.5	D15	D15.5	D16	D16.5	D17	D17.5	D18	D19
01-002	15.5	956		2251	417	5035	3779		182		168		
01-003	12.5		17		N							N	
01-005	15	2666	2999	4700	1538	17795	14843		13925		1324	246	
01-006	15	1331		2632	1056	8687	7112		294		154		
01-007	15.5	1431	1253	3054	1444	9597	8134	15768		555		355	
01-009	16.5	239		717		1479	1438	2593	9668	7894		534	464

Table S4: Raw qPCR data (genome copies/mL) for VAC069A.

Top row represents day of follow-up visit post blood-stage CHMI. Data highlighted in red represent qPCR measurement at time-point of diagnosis according to protocol, also referred to as "day of diagnosis" (DoD) for a particular individual. N = PCR negative for all three triplicate readings in the assay. Squares highlighted in grey indicate negative or a mean reading <20 gc/mL (below minimum positive reporting criteria). Squares highlighted in orange indicate a sample taken immediately pre-treatment at the next clinic visit following diagnosis; where this occurs, volunteers were officially diagnosed based on symptoms and/or qPCR and/or thick film microscopy data obtained in real time between clinic visits. Squares highlighted in blue indicate samples taken post-treatment.

Volunteer	Grade 3 AE	Time-point	Persisted at Grade 3	Resolution
01-002	Feverishness	T+1	24 hours	T+2
	Feverishness	Diagnosis/C+12.5	48 hours	T+2
	Chills	T+1	24 hours	T+2
01 003	Sweats	T+1	24 hours	T+2
01-003	Myalgia	T+1	24 hours	T+2
	Fatigue	T+1	24 hours	C+28
	Malaise	T+1	24 hours	T+2
	Feverishness	T+1	24 hours	T+2
	Chills	T+1	24 hours	T+2
01-006	Headache	T+1	24 hours	T+2
	Fatigue	T+1	24 hours	T+2
	Malaise	T+1	24 hours	T+2
01 000	Feverishness	T+1	24 hours	T+2
01-009	Rigor	T+1	24 hours	T+2

В

MEDDRA System Organ Class	MEDDRA Higher Level Term	MEDDRA Preferred Term	Subject ID (diagnosis day)	Onset (days post-CHMI)	AE duration (days)	Maximum severity
Skin and subcutaneous tissue disorders	Pruritus NEC	Pruritus	01-003 (C+12.5)	0	1	Grade 1
Metabolism and nutrition disorders	Appetite disorders	Decreased appetite	01-003 (C+12.5)	11	4	Grade 2
Musculoskeletal and connective tissue disorders	Muscle pains	Myalgia	01-006 (C+15)	11	1	Grade 1

Α

С					
Laboratory AE	Volunteer	Time-point	Result	Grade	Action taken
	01-002	T+6	119	1	Repeated and resolved at next visit (C+28)
Anaemia (g/L)	01-005	C+16, C+34 (C+14-C+90)	98 (98-109)	(1-)2	Monitored from C+14 to C+90, AE ongoing at C+90 (102 g/L; Grade 1) Referred to General Practitioner for ongoing medical care, with follow-up of AE ongoing
	01-002	T+1	3.3	1	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved (6.53 x10 ⁹ /L) at next visit (T+6)
Low white	01-003	T+1	2.93	1	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved (6.86 x10 ⁹ /L) at next visit (T+6)
Low white blood cell count (x10 ⁹ /L)	01-005	T+1 (C+7-C+90)	1.68 (1.68-3.39)	(1-)2	Monitored from C+7 to C+90, AE ongoing at C+90 (3.36 x10 ⁹ /L; Grade1) Referred to General Practitioner for monitoring / ongoing care
	01-006	T+1 (C+14-T+1)	2.36	2	Monitored from C+14 to T+6, resolved at T+6 (4.84 x10 ⁹ /L); consistent with <i>P. vivax</i> diagnosis
Thrombocyto-	01-003	T+1	114	2	Consistent with <i>P. vivax</i> diagnosis; repeated and resolved (233 x10 ⁹ /L) at next visit (T+6)
paenia (x10 ⁹ /L)	01-005	T+1 (Diagnosis- T+1)	115 (115-127)	(1-)2	Consistent with <i>P. vivax</i> diagnosis; repeated and resolved at T+6 (219 x10 ⁹ /L)
Neutropaenia (x10 ⁹ /L)	01-005	C+45 (C+14-C+90)	0.76 (0.76-1.46)	(1-)2	Monitored from C+14 to C+90, AE ongoing at C+90 (1.26 x10 ⁹ /L; Grade 1) Referred to General Practitioner for monitoring / ongoing care
	01-002	T+1 (Diagnosis- T+1)	0.72 (0.72-0.86)	(1-)2	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved at T+6 (1.63 x10 ⁹ /L)
Lymphocyto-	01-003	T+1	0.77	1	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved at T+6 (2.53 x10 ⁹ /L)
(x10 ⁹ /L)	01-005	Diagnosis (Diagnosis- T+1)	0.44 (0.44-0.63)	(2-)3	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved at T+6 (1.63 x10 ⁹ /L)
	01-006	T+1 (C+14-T+1)	0.3 (0.3-0.83)	(1-)3	Consistent with <i>P. vivax</i> diagnosis, repeated and resolved at T+6 (2.07 x10 ⁹ /L)

D

Laboratory AE	Volunteer	Time-point	Result	Grade	Action taken
Hyponatraemia	01-003	C+28	134	1	No clinical concern, no action taken
(mmol/L)	01-003	C+90	134	1	No clinical concern, no action taken
	01-002	C+90	3.3	1	No clinical concern, no action taken
Hypokalaemia (mmol/L)	01-005	Diagnosis	3.3	1	Repeated within 24 hours at next visit, resolved (3.7 mmol/L)
	01-003	C+90	3.3	1	No clinical concern, no action taken
	01-003	T+6	135	2	Asymptomatic, repeated in 48 hours (80 IU/L; Grade 1) and then resolved at C+28 (21 IU/L)
ALT	01-006	T+6	56	1	Repeated at next visit (C+28) and resolved (29 IU/L)
(IU/L)	01-007	T+6	80	1	Repeated at next visit (C+28) and resolved (31 IU/L)
	01-009	T+6	114	2	Asymptomatic, repeated in 72 hours and resolved (40 IU/L)

Table S5: VAC069A grade 3, unsolicited and laboratory AEs.

(A) Onset and duration of grade 3 solicited AEs reported by all volunteers (n=6) in the VAC069A study. (B) Unsolicited AEs deemed at least possibly (possibly, probably or definitely) related to *P*. *vivax* PvW1 blood-stage CHMI in all volunteers (n=6) in the VAC069A study. These were assigned a MedDRA code, with maximum severity reported. (C) Laboratory AEs in full blood count in all volunteers (n=6) in the VAC069A study. (D) Laboratory AEs in biochemistry profile (urea and electrolytes, liver function tests). ALT = alanine aminotransferase. Maximum reported severity is shown, graded as per site-specific grading tables; (Grading: 1 = mild; 2 = moderate; 3 = severe). In all panels, time-point(s) = days in relation to day of CHMI (C) or treatment (T).

Supplementary References

- 1. Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, et al. Genetic surveillance in the Greater Mekong Subregion and South Asia to support malaria control and elimination. *medRxiv*. 2020:2020.07.23.20159624.
- 2. Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, antimalarial drug primaquine. *Malar J*. 2012;11:259.
- 3. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria. *N Engl J Med.* 2013;369(14):1381-2.
- 4. Auburn S, Bohme U, Steinbiss S, Trimarsanto H, Hostetler J, Sanders M, et al. A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. *Wellcome open research*. 2016;1:4.
- 5. Rice BL, Acosta MM, Pacheco MA, Carlton JM, Barnwell JW, and Escalante AA. The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites. *Mol Phylogenet Evol.* 2014;78:172-84.
- 6. Payne RO, Silk SE, Elias SC, Milne KH, Rawlinson TA, Llewellyn D, et al. Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. *JCI Insight*. 2017;2(12):93683.
- 7. Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, et al. Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial. *NPJ Vaccines*. 2018;3:48.
- 8. Chen E, Salinas ND, Ntumngia FB, Adams JH, and Tolia NH. Structural Analysis of the Synthetic Duffy Binding Protein (DBP) Antigen DEKnull Relevant for Plasmodium vivax Malaria Vaccine Design. *PLoS Negl Trop Dis.* 2015;9(3):e0003644.
- 9. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. *Pharmacogenomics J.* 2009;9(1):34-41.
- 10. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, and Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther.* 2008;83(2):234-42.